Your browser doesn't support javascript.
loading
Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration.
Ophthalmic Surg Lasers Imaging Retina ; 47(5): 458-65, 2016 05 01.
Article in En | MEDLINE | ID: mdl-27183550

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Receptors, Vascular Endothelial Growth Factor / Wet Macular Degeneration / Drug Substitution / Bevacizumab / Ranibizumab / Macula Lutea Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 / Female / Humans / Male Language: En Journal: Ophthalmic Surg Lasers Imaging Retina Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Receptors, Vascular Endothelial Growth Factor / Wet Macular Degeneration / Drug Substitution / Bevacizumab / Ranibizumab / Macula Lutea Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 / Female / Humans / Male Language: En Journal: Ophthalmic Surg Lasers Imaging Retina Year: 2016 Document type: Article